With an improved median survival of 6.2 years, lung transplantation has become an
increasingly acceptable treatment option for end-stage lung disease. Besides survival …

HLA antigens are polymorphic proteins expressed on donor kidney allograft endothelium
and are critical targets for recipient immune recognition. HLA antibodies are risk factors for …

Background Antibody-mediated rejection (AMR) after lung transplantation remains
enigmatic, and there is no consensus on the characteristic clinical, immunologic and …

Advances in immunosuppressive therapy have drastically improved acute rejection rates in
kidney transplant recipients over the past five decades. Nevertheless, it should remain high …

There has been increasing interest in the role played by B cells, plasma cells and their
associated antibody in the immune response to an allograft, driven by the need to undertake …

ABO incompatibility is no longer considered a contraindication for adult living donor liver
transplantation (ALDLT) due to various strategies to overcome the ABO blood group barrier …

Antibody‐mediated rejection (AMR), also known as B‐cell–mediated or humoral rejection, is
a significant complication after kidney transplantation that carries a poor prognosis. Although …

Background. Antibody-mediated rejection (ABMR) following kidney transplantation is
associated with poor allograft survival. Conventional treatment based on plasmapheresis …

Introduction Antibody-mediated rejection (ABMR) is a leading cause of kidney allograft
failure. Its therapy continues to be challenge, and no treatment has been approved for the …

For kidney transplant recipients, immunosuppression commonly consists of combination
treatment with a calcineurin inhibitor, an antiproliferative agent and a corticosteroid. Many …